Table 3.
Adverse cardiovascular events during the follow up period.
| Outcome | G1 n = 92 |
G2 n = 92 |
HR | 95% CI | p-Value |
|---|---|---|---|---|---|
| MACE, n (%) | 20 (21.7) | 18 (19.7) | 1.15 | (0.61–2.19) | 0.65 |
| Overall mortality, n (%) | 11 (12) | 10 (10.9) | 1.09 | (0.46–2.56) | 0.85 |
| CV death, n (%) | 7 (7.3) | 4 (4.3) | 1.72 | (0.50–5.89) | 0.39 |
| Stroke/TIA, n (%) | 1 (1.1) | 1 (1.1) | 0.99 | (0.06–15.90) | 1 |
| AMI, n (%) | 2 (2.2) | 3 (3.3) | 0.66 | (0.11–4.02) | 0.66 |
| CV Hospitalization, n (%) | 19 (20.7) | 14 (15.2) | 1.34 | (0.67–2.68) | 0.40 |
| Hospitalization due to HF, n (%) | 18 (19.6) | 9 (9.8) | 2.07 | (0.93–4.61) | 0.07 |
| Follow up, months (±SD) | 11.5 ± 1.7 | 11.3 ± 2.1 | 0.65 |
MACE: major adverse cardiovascular events; CV: cardiovascular; TIA: transient ischemic attack; AMI: acute myocardial infraction; HF: heart failure; HR: hazard ratio; CI: confidence interval.